NCT02405364 - Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions

Multiple Myeloma

Interventions

DRUG

Carfilzomib/Lenalidomide/Dexamethasone

Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)

Trial Locations (11)

31000

CHU de Toulouse, Toulouse

University hospital of Toulouse, Toulouse

Unknown

CHU Henri Mondor, Créteil

CHRU Dijon, Dijon

CHU Grenoble, Grenoble

Hôpital Claude Huriez, Lille

CHRU Hôtel Dieu, Nantes

Hôpital Saint-Antoine, Paris

Hôpital de Pontchaillou, Rennes

Hôpital de Hautepierre, Strasbourg

Hôpital Bretonneau, Tours